Edition:
United States

People: Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

8.95USD
19 Jun 2018
Change (% chg)

-- (--)
Prev Close
$8.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,813
52-wk High
$9.49
52-wk Low
$1.29

Horton, J. Rex 

Mr. J. Rex Horton is an Executive Director - Regulatory Affairs and Quality Assurance of Galectin Therapeutics Inc., since January 15, 2013. Mr. Horton most recently was Director of Regulatory Affairs at Chelsea Therapeutics, where he successfully led the organization through its first NDA filing and favorable FDA Advisory Committee Meeting. In past leadership roles at Solvay Pharmaceuticals and Abbott Laboratories, he led approval efforts for key products including Androgel® Stickpack, Creon® Capsules and Luvox® CR Capsules. He has also provided chemistry, manufacturing and controls (CMC) regulatory leadership and support of INDs and NDAs, including Estrogel® and Androgel® Pump. Mr. Horton was a member of the executive leadership team that successfully implemented solutions to significant regulatory issues encountered by Solvay in its interactions with the FDA. Mr. Horton earned his Bachelor’s degree in industrial/manufacturing & systems engineering from The Georgia Institute of Technology. He is a member of the Regulatory Affairs Professional Society (RAPS), Drug Information Association (DIA) and American Association of Pharmaceutical Scientists (AAPS).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Marc Rubin

--

Peter Traber

2,252,050

Jack Callicutt

545,714

Harold Shlevin

771,748

Eliezer Zomer

134,471

J. Rex Horton

--
As Of  30 Dec 2014